IN2012DN02596A - - Google Patents

Info

Publication number
IN2012DN02596A
IN2012DN02596A IN2596DEN2012A IN2012DN02596A IN 2012DN02596 A IN2012DN02596 A IN 2012DN02596A IN 2596DEN2012 A IN2596DEN2012 A IN 2596DEN2012A IN 2012DN02596 A IN2012DN02596 A IN 2012DN02596A
Authority
IN
India
Prior art keywords
activity
molecules
protein kinase
kinase
relates
Prior art date
Application number
Inventor
Fabirce PIERRE
Mustapha Haddach
Collin F Regan
David M Ryckman
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of IN2012DN02596A publication Critical patent/IN2012DN02596A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS The invention relates in part to molecules having certain biological activities that include but are not limited to inhibiting cell proliferation modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
IN2596DEN2012 2009-08-26 2010-08-26 IN2012DN02596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23722709P 2009-08-26 2009-08-26
US28931709P 2009-12-22 2009-12-22
PCT/US2010/046760 WO2011025859A1 (en) 2009-08-26 2010-08-26 Condensed quinolines as protein kinase modulators

Publications (1)

Publication Number Publication Date
IN2012DN02596A true IN2012DN02596A (en) 2015-08-28

Family

ID=42983433

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2596DEN2012 IN2012DN02596A (en) 2009-08-26 2010-08-26

Country Status (13)

Country Link
US (1) US20110065698A1 (en)
EP (1) EP2470544A1 (en)
JP (1) JP2013503178A (en)
KR (1) KR20120059571A (en)
CN (1) CN102596969A (en)
AU (1) AU2010286691A1 (en)
BR (1) BR112012004304A2 (en)
CA (1) CA2771890A1 (en)
IL (1) IL218280A0 (en)
IN (1) IN2012DN02596A (en)
MX (1) MX2012002426A (en)
SG (1) SG178552A1 (en)
WO (1) WO2011025859A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
BR112015016793B1 (en) 2013-01-15 2021-12-28 Incyte Holdings Corporation COMPOUNDS OF THIAZOLACARBOXAMIDES AND PYRIDINECARBOXAMIDE, COMPOSITION COMPRISING THE SAME, METHOD OF INHIBITING THE ENZYME PIM1, PIM2, OR PIM3, AND USES OF SUCH COMPOUNDS
AR097431A1 (en) 2013-08-23 2016-03-16 Incyte Corp FUR CARBOXAMIDE COMPOUNDS AND TIENOPIRIDINE USEFUL AS PIM KINASE INHIBITORS
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN111031799A (en) * 2017-07-03 2020-04-17 拜耳作物科学股份公司 Substituted isothiazolopyridinones, method for the production thereof and use thereof as herbicides and/or plant growth regulators
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1218358B1 (en) 1999-09-23 2006-09-13 AstraZeneca AB Therapeutic quinazoline compounds
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
MX2007010063A (en) 2005-02-17 2008-01-16 Albany Molecular Res Inc Benzoxazole carboxamides for treating cinv and ibs-d.
CA2661842C (en) * 2006-09-01 2017-08-22 Cylene Pharmaceuticals, Inc. Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators
MX2010009445A (en) * 2008-02-29 2011-05-25 Cylene Pharmaceuticals Inc Protein kinase modulators.
US20100120741A1 (en) * 2008-09-10 2010-05-13 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
KR20120059571A (en) 2012-06-08
BR112012004304A2 (en) 2016-03-15
IL218280A0 (en) 2012-04-30
WO2011025859A1 (en) 2011-03-03
US20110065698A1 (en) 2011-03-17
JP2013503178A (en) 2013-01-31
SG178552A1 (en) 2012-03-29
MX2012002426A (en) 2012-06-27
CA2771890A1 (en) 2011-03-03
EP2470544A1 (en) 2012-07-04
CN102596969A (en) 2012-07-18
AU2010286691A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
IN2012DN02596A (en)
MX2009002298A (en) Serine-threonine protein kinase and parp modulators.
MX341591B (en) Benzoxazole kinase inhibitors and methods of use.
WO2010006086A3 (en) Kinase inhibitors and methods of use
MY168757A (en) Novel compounds as modulators of protein kinases
PH12015501370A1 (en) Compounds and methods for kinase modulation, and indications therefor
UA97816C2 (en) Compounds modulating c-kit and/or c-fms activity and use thereof
WO2012037155A3 (en) Tyrosine kinase inhibitors
EA200901308A1 (en) INHIBITORS OF PROTEIN ACTIVATING 5-LIPOXYGENASE (FLAP)
MX2009012623A (en) Heterocyclic kinase modulators.
EA201790267A1 (en) NEW KINAZ MODULATORS
EA201490695A1 (en) SLIP PROTEINS FOR THE TREATMENT OF METABOLISM DISORDERS
BR112014023162A8 (en) compounds and methods for kinase modulation and indications thereof
WO2011090738A3 (en) Type ii raf kinase inhibitors
EA200970729A1 (en) OPTIONS FROM ACTRIIB, AND THEIR APPLICATION
WO2009097014A3 (en) Therapeutic kinase modulators
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
PH12016500432A1 (en) Inhibitors of erk and methods of use
GT200600254A (en) AMINOQUINOLINE AND AMINOQUINAZOLINE QUINASA MODULATORS
MX2011006290A (en) Azaazulene compounds.
EA201300867A1 (en) MTOR KINASE INHIBITORS AS ANTI-VIRUS AGENTS
UA101814C2 (en) Factor employed in latent herpesvirus infection and its using
IN2014DN03295A (en)
WO2011097327A3 (en) Compositions and methods of modulating receptor protein tyrosine phosphatases
MX2010001187A (en) Modulators of ccr9 receptor and methods of use thereof.